Retrospective study of the effectiveness and safety of Ustekinumab in refractory Crohn's Disease by Truyens, Marie et al.
A total of 51 patients were included, of which the majority were
refractory to TNF inhibitors and/or vedolizumab (table 1). The
median duration of follow-up was 45 weeks (IQR 24-69). UST was
discontinued in 11 patients (21.6%) after a median of 26 weeks
(IQR 10-34). Reasons for discontinuation are shown below.
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Ustekinumab (UST) is used increasingly in Belgium to treat
moderate to severe Crohn’s disease (CD). The goal of this study
was to describe the effectiveness of UST in our tertiary center.
Retrospective study of the effectiveness and safety of Ustekinumab in refractory Crohn’s Disease
In this population of refractory CD patients, UST was efficacious
to induce and maintain clinical remission. Endoscopic and
radiological response in these preliminary analyses were
modest.
A retrospective monocentric study was performed in patients with
CD who were started on UST between December 2017 and
December 2018.
UST dosing:
• Intravenous dose (6 mg/kg)
Followed by:
• Subcutaneous UST (90 mg, q8)
The clinical, endoscopic and radiological response was
assessed during the follow-up. A biological response was defined
as a decrease of ≥50% in C-reactive protein (CRP) and/or fecal





Age (years), median [IQR] 41.7 [32.4-53]
Age at diagnosis (years), median [IQR] 24.5 [18-34.8]
Duration of disease (years), median [IQR] 12 [8-21]
History of resection, n [%] 29 [58]
Extra-intestinal manifestations, n [%] 19 [37.3]
Corticosteroids at baseline, n [%] 24 [47.1]





















A biological response was achieved in 8/37 patients (21.6%) and
biological remission in 16/37 (43.2%), the remaining patients
(35.1%) showed no response. Endoscopy was performed in 20
patients and an endoscopic response was confirmed in 10/20
patients (50%), remission in 2 patients (10%). The other 8





The clinical response at short term (4-8 weeks after the initial IV
induction), could be assessed in 43 patients. 27/43 patients had a
response and 4 patients were in clinical remission. In 12 patients
no response was seen.
During the maintenance phase patients were assessed at a
median of 26 weeks (IQR 23-39). A clinical response in the
maintenance period was seen in 25/51 patients (49%) and an
additional 12 patients (23.5%) reached remission.
Ten patients (19.6%) were hospitalized for IBD-
related complications, most of them for surgery
(9/10). Other adverse events (AEs) occurred in 11
patients, most often arthralgia. One patient
developed a flare of an underlying
spondyloarthropathy and UST was discontinued. A
paradoxical worsening of psoriasis was observed in
1 patient.
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Radiological evaluation was performed in 21 patients of which
12 showed no response (57.1%), 7/21 (33.3%) had a response
and 2 (9.5%) were in radiological remission.
